Cyamemazine
Cyamemazine structure
|
Common Name | Cyamemazine | ||
|---|---|---|---|---|
| CAS Number | 3546-03-0 | Molecular Weight | 323.455 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 479.0±45.0 °C at 760 mmHg | |
| Molecular Formula | C19H21N3S | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 243.5±28.7 °C | |
| Symbol |
GHS09 |
Signal Word | Warning | |
Use of CyamemazineCyamemazine is a neuroleptic agent that contains the phenothiazine chromophore. Cyamemazine is often used as an anxiolytic. Cyamemazine is a potent 5-HT3 (Ki of 12 nM), 5-HT2A (Ki = 1.5 nM) and 5-HT2C (Ki of 75 nM) receptors antagonist with antipsychotic activity[1][2]. |
| Name | Cyamemazine |
|---|---|
| Synonym | More Synonyms |
| Description | Cyamemazine is a neuroleptic agent that contains the phenothiazine chromophore. Cyamemazine is often used as an anxiolytic. Cyamemazine is a potent 5-HT3 (Ki of 12 nM), 5-HT2A (Ki = 1.5 nM) and 5-HT2C (Ki of 75 nM) receptors antagonist with antipsychotic activity[1][2]. |
|---|---|
| Related Catalog | |
| Target |
5-HT2A Receptor:1.5 nM (Ki) 5-HT2C Receptor:12 nM (Ki) 5-HT3 Receptor:75 nM (Ki) |
| In Vitro | Cyamemazine exhibits a high affinity for dopamine receptors, which is consistent with its antipsychotic activity. The antagonist activity of Cyamemazine at muscarinic receptors is consistent with its affinity for M1 (Ki = 13 nM), M2 (Ki = 42 nM), M3 (Ki = 321 nM), M4 (Ki = 12 nM), and M5 (Ki = 35 nM) receptors[1]. |
| In Vivo | Cyamemazine behaves as an antagonist at the 5-HT3, 5-HT2C, and 5-HT2A receptors in 5-HT3-dependent contraction of isolated guinea pig ileum and bradycardic responses in rats, in 5-HT2C-dependent phospholipase C stimulation in the rat brain membrane, and in 5-HT2A-dependent contraction of isolated rat aorta rings and isolated guinea pig trachea. Cyamemazine antagonizes 5-HT3 and 5-HT2C receptors and that this effect is partially involved in its therapeutic activity in anxiety disorders. Acute administration of low doses of Cyamemazine can reduces extracellular dopamine and metabolite concentrations in rat striatum[1]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 479.0±45.0 °C at 760 mmHg |
| Molecular Formula | C19H21N3S |
| Molecular Weight | 323.455 |
| Flash Point | 243.5±28.7 °C |
| Exact Mass | 323.145630 |
| PSA | 55.57000 |
| LogP | 4.62 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.655 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
|
~0%
Cyamemazine CAS#:3546-03-0 |
| Literature: Singh, Gurmit; Koerner, Terry B.; Godefroy, Samuel Benrejeb; Armand, Claude Bioorganic and Medicinal Chemistry Letters, 2012 , vol. 22, # 6 p. 2160 - 2162 |
|
~%
Cyamemazine CAS#:3546-03-0 |
| Literature: Journal of Organic Chemistry, , vol. 26, p. 1138 - 1143 |
|
~%
Cyamemazine CAS#:3546-03-0 |
| Literature: Journal of Organic Chemistry, , vol. 26, p. 1138 - 1143 |
|
~%
Cyamemazine CAS#:3546-03-0 |
| Literature: US2877224 , ; |
|
~%
Cyamemazine CAS#:3546-03-0 |
| Literature: US2877224 , ; |
|
~%
Cyamemazine CAS#:3546-03-0 |
| Literature: Journal of Organic Chemistry, , vol. 26, p. 1138 - 1143 |
![10-[2-methyl-3-(methylamino)propyl]phenothiazine-2-carbonitrile structure](https://image.chemsrc.com/caspic/205/108014-19-3.png)
| HS Code | 2934300000 |
|---|---|
| Summary | 2934300000. other compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Identification and quantification of 35 psychotropic drugs and metabolites in hair by LC-MS/MS: application in forensic toxicology.
Int. J. Legal Med. 129(2) , 259-68, (2015) Despite a non-invasive sampling, hair samples are generally collected in limited amounts for an obvious esthetic reason. In order to reduce the required quantity of samples, a multianalytes method all... |
|
|
Fatal intoxication with milnacipran
J. Forensic Leg. Med. 15(6) , 388-90, (2008) The antidepressant milnacipran is a double serotonin/noradrenalin reuptake inhibitor. The low reported incidence of intoxication indicates excellent tolerance in comparison with tricyclic and second g... |
|
|
Prise en charge médicamenteuse de l’anxiété chez le patient souffrant de schizophrénie
Encephale 37 Suppl 1 , S83-9, (2011) L’anxiété est un symptôme fréquent et majeur de la schizophrénie. Elle est un symptôme clinique dominant dans la phase prodromique [indice de progression vers la « décompensation psychotique »] et acc... |
| Kyamepromazin |
| Kyamepromazine |
| 10H-Phenothiazine-2-carbonitrile, 10-[3-(dimethylamino)-2-methylpropyl]- |
| 7204 R.E. |
| Ciamatil |
| Cyamemazine |
| 10-[3-(Dimethylamino)-2-methylpropyl]-10H-phenothiazine-2-carbonitrile |
| 2-Cyano-10-(3-dimethylamino-2-methylpropyl)phenothiazine |
| Tercian |
| 10-[3-(dimethylamino)-2-methylpropyl]phenothiazine-2-carbonitrile |